Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREND-02: Sacituzumab Govitecan Plus Tislelizumab in Early TNBC
NCT07271992Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Dec 2025
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of sacituzumab govitecan, tislelizumab in triple-negative breast cancer (TNBC), sponsored by First Hospital of China Medical University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sacituzumab govitecantislelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07271992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07271992.